Home » Edwards Lifesciences Responds to CMS’s Proposed TAVR National Coverage Determination
Edwards Lifesciences Responds to CMS’s Proposed TAVR National Coverage Determination
Edwards Lifesciences reported that on March 3, 2012, the company filed its official response to the Centers for Medicare & Medicaid Services on its Proposed National Coverage Determination for Transcatheter Aortic Valve Replacement.
Qmed
Qmed
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May